Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2017-01-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-16-0644PMID 28138033PMCID PMC5445934
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.

  2016cited by this paper
• Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer

  2015cited by this paper
• Antioxidants can increase melanoma metastasis in mice

  2015cited by this paper
• Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis.

  2015cited by this paper
• NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling

  2014cited by this paper
• The Quest for Selective Nox Inhibitors and Therapeutics: Challenges, Triumphs and Pitfalls

  2014cited by this paper
• Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.

  2013cited by this paper
• Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.

  2013cited by this paper
• Differential Post-Surgical Metastasis and Survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγnull Mice with Parental and Subline Variants of Human Breast Cancer: Implications for Host Defense Mechanisms Regulating Metastasis

  2013cited by this paper
• Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells

  2012cited by this paper
• Polo-like kinase 1 as target for cancer therapy

  2012cited by this paper
• Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells.

  2012cited by this paper
• Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

  2012cited by this paper
• Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

  2011influential reference
• Targeting Polo-like Kinase in Cancer Therapy

  2010cited by this paper
• Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression.

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Reactive oxygen species in cancer

  2010cited by this paper
• Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts

  2009cited by this paper
• Tks5-Dependent, Nox-Mediated Generation of Reactive Oxygen Species Is Necessary for Invadopodia Formation

  2009influential reference
• Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin.

  2008cited by this paper
• In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

  2007cited by this paper
• The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression

  2007cited by this paper
• Silicon and bone health.

  2007cited by this paper
• Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.

  2006cited by this paper
• Effect of High-Dose Intravenous N-acetylcysteine on the Concentration of Plasma Sulfur-Containing Amino Acids

  2005influential reference
• Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues

  2005cited by this paper
• The Proton Sponge: a Trick to Enter Cells the Viruses Did Not Exploit

  1997cited by this paper
• International Agency for Research on Cancer.

  1985cited by this paper

• Stilbenes in Breast Cancer Treatment: Nanostilbenes an Approach to Improve Therapeutic Efficacy

  2025cites this paper
• Tumor microenvironment-responsive nanoparticles composed of hyaluronic acid and stearic acid for the treatment of lung metastasis in triple-negative breast cancer.

  2025cites this paper
• Knocking on Cells’ Door: Strategic Approaches for miRNA and siRNA in Anticancer Therapy

  2025cites this paper
• Intelligent nanoparticles loaded simultaneously with anti-PD-L1 and anti-CTLA-4 for photothermal immunotherapy of lung cancer

  2025cites this paper
• Nanomedicine-Enhanced Radiotherapy for Glioblastoma: Advances in Targeted Therapy and Adaptive Treatment Strategies

  2025cites this paper
• Nanoparticulate systems for combination therapies of lung cancer: A review

  2025cites this paper
• Polymeric functionalization of mesoporous silica nanoparticles: Biomedical insights.

  2024cites this paper
• Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications

  2024cites this paper
• Biomimetic Modification of siRNA/Chemo Drug Nanoassemblies for Targeted Combination Therapy in Breast Cancer.

  2024cites this paper
• Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy

  2024cites this paper
• Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises

  2024cites this paper
• The dark side of PLK1: Implications for cancer and genomic instability

  2023cites this paper
• Biofunctionalized Decellularized Tissue-Engineered Heart Valve with Mesoporous Silica Nanoparticles for Controlled Release of VEGF and RunX2-siRNA against Calcification

  2023cites this paper
• Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemo- and radioresistances.

  2023cites this paper
• Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer

  2022cites this paper
• WINNER: A network biology tool for biomolecular characterization and prioritization

  2022cites this paper
• Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

  2022cites this paper
• Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress

  2022cites this paper
• siRNA-based nanocarriers for targeted drug delivery to control breast cancer

  2022cites this paper
• Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials

  2022cites this paper
• Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis.

  2022cites this paper
• Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment

  2021cites this paper
• Newly Developed Self-Assembling Antioxidants as Potential Therapeutics for the Cancers

  2021cites this paper
• Breast Cancer and the Other Non-Coding RNAs

  2021influential citation
• AS1411-functionalized delivery nanosystems for targeted cancer therapy

  2021cites this paper
• Aptamer-Assisted Delivery of Nucleotides with Tumor-Suppressing Properties for Targeted Cancer Therapies

  2021cites this paper
• Mesoporous silica-biopolymer-based systems in drug delivery applications

  2021cites this paper
• Silybum marianum seed disrupts mitosis by reducing polo-like kinase 1 in breast cancer cells

  2021cites this paper
• Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.

  2020cites this paper
• A Strategy to Fight against Triple-Negative Breast Cancer: pH-Responsive Hexahistidine-Metal Assemblies with High-Payload Drugs.

  2020cites this paper
• Silica-Based Gene Delivery Systems: From Design to Therapeutic Applications

  2020cites this paper
• Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

  2020cites this paper
• Synthetic amorphous silica nanoparticles: toxicity, biomedical and environmental implications

  2020cites this paper
• Systemic Delivery of NAC-1 siRNA by Neuropilin-Targeted Polymersomes Sensitizes Antiangiogenic Therapy of Metastatic Triple-Negative Breast Cancer.

  2020cites this paper
• PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.

  2019cites this paper
• siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion.

  2019cites this paper
• Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer

  2019cites this paper
• Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis

  2019cites this paper
• M-CSF on hypoxia-inducible factor-1α (HIF-1α)/BCL2/adeno- virus E1B 19 kDa-interacting protein 3 (BNIP3)/Apoptosis Regulator BAX signalling in human breast cancer MCF-7 cells were investigated. Western blotting revealed that the expression of HIF-1α, BNIP3, Bax, caspase-3 and caspase-9 was lower in

  2019cites this paper
• Therapeutic Potential of Polymer-Coated Mesoporous Silica Nanoparticles

  2019cites this paper
• Identification of key molecular targets that correlate with breast cancer through bioinformatic methods

  2019cites this paper
• Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery

  2019cites this paper
• Cooperativity Principles in Self-Assembled Nanomedicine.

  2018cites this paper
• Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer

  2018cites this paper
• Non-viral gene therapy using multifunctional nanoparticles: Status, challenges, and opportunities

  2018cites this paper
• MiRNA-224-5p inhibits autophagy in breast cancer cells via targeting Smad4.

  2018cites this paper
• Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

  2018cites this paper
• Nitroxide radical-containing nanoparticles attenuate tumorigenic potential of triple negative breast cancer.

  2018cites this paper
• Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment

  2018cites this paper
• Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.

  2017cites this paper
• The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis

  2017cites this paper
• RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T‐acute lymphoblastic leukemia patients

  2017cites this paper